EP Patent

EP3856182A1 — Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Assigned to Karuna Therapeutics Inc · Expires 2021-08-04 · 5y expired

What this patent protects

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

USPTO Abstract

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Drugs covered by this patent

Patent Metadata

Patent number: EP3856182A1
Jurisdiction: EP
Classification: —
Expires: 2021-08-04
Drug substance claim: No
Drug product claim: No
Assignee: Karuna Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.